Forums before death by AOL, social media and spammers... "We can't have nice things"
|    sci.med.psychobiology    |    Dialog and news in psychiatry and psycho    |    4,734 messages    |
[   << oldest   |   < older   |   list   |   newer >   |   newest >>   ]
|    Message 3,089 of 4,734    |
|    23x to All    |
|    Nicotinamide Restores Cognition in Alzhe    |
|    29 Oct 14 11:05:12    |
      From: drarwingnuttephd@gmail.com              Nicotinamide Restores Cognition in Alzheimer's Disease Transgenic Mice via a       Mechanism Involving Sirtuin Inhibition and Selective Reduction of       Thr231-Phosphotau       Kim N. Green1, Joan S. Steffan2, Hilda Martinez-Coria1, Xuemin Sun3, Steven S.       Schreiber3,5, Leslie Michels Thompson1,2,4, and Frank M. LaFerla1       +Show Affiliations       The Journal of Neuroscience, 5 November 2008, 28(45): 11500-11510; doi:       10.1523/JNEUROSCI.3203-08.2008              Abstract              Memory loss is the signature feature of Alzheimer's disease, and therapies       that prevent or delay its onset are urgently needed. Effective preventive       strategies likely offer the greatest and most widespread benefits. Histone       deacetylase (HDAC) inhibitors        increase histone acetylation and enhance memory and synaptic plasticity. We       evaluated the efficacy of nicotinamide, a competitive inhibitor of the       sirtuins or class III NAD+-dependent HDACs in 3xTg-AD mice, and found that it       restored cognitive deficits        associated with pathology. Nicotinamide selectively reduces a specific       phospho-species of tau (Thr231) that is associated with microtubule       depolymerization, in a manner similar to inhibition of SirT1. Nicotinamide       also dramatically increased acetylated α       -tubulin, a primary substrate of SirT2, and MAP2c, both of which are linked to       increased microtubule stability. Reduced phosphoThr231-tau was related to a       reduction of monoubiquitin-conjugated tau, suggesting that this        osttranslationally modified form        of tau may be rapidly degraded. Overexpression of a Thr231-phospho-mimic tau       in vitro increased clearance and decreased accumulation of tau compared with       wild-type tau. These preclinical findings suggest that oral nicotinamide may       represent a safe        treatment for AD and other tauopathies, and that phosphorylation of tau at       Thr231 may regulate tau stability.                     http://www.jneurosci.org/content/28/45/11500.abstract              --- SoupGate-Win32 v1.05        * Origin: you cannot sedate... all the things you hate (1:229/2)    |
[   << oldest   |   < older   |   list   |   newer >   |   newest >>   ]
(c) 1994, bbs@darkrealms.ca